И. Б. Кононенко
49 works · 72 citations · h-index 5
Top works
- A case of uremic pruritus and papulo-pustular rash associated with anti-EGFR therapy in a patient with rectal cancer and chronic kidney disease
- Dermatological toxicity of EGFR inhibitors: pathogenetic rationale and an algorithm for acne-like rash correction
- THE DEVELOPMENT OF THE STRATEGIC APPROACHES TO MODERN DIAGNOSIS OF ANEMIC SYNDROME IN PATIENTS WITH BREAST CANCER
- Anemias in Oncology: Potential of Maintenance Therapy
- Analysis of the −238(G/A)TNF polymorphism in breast-cancer patients
- Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study
- Cyclin-dependent kinase inhibitors: efficacy and safety
- The role of interleukin-6 and hepcidin 25 in the pathogenesis of anemic syndrome associated with malignant neoplasms with breast cancer patients before neoadjuvant chemotherapy
- Chemotherapy limiting neutropenia. Is prevention required?
- Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
- THE ROLE OF HEPCIDIN 25 IN THE DEVELOPMENT OF ANEMIC SYNDROME ASSOCIATED WITH MALIGNANT DISEASES
- Defendor: Real-world evidence of primary prolonged G-CSF prophylaxis by empegfilgrastim for relative dose intensity compliance in patients with solid tumors—The primary analysis.
- Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients
- Anorexia-cachexia syndrome in cancer patients: pathogenetic aspects and treatment options
- Peculiarities of iron metabolism in patients with breast cancer before adjuvant chemotherapy
- DIAGNOSTICS AND TREATMENT OF ANEMIC SYNDROME IN PATIENTS WITH BREAST CANCER ON THE BACKGROUND OF NEOADJUVANT CHEMOTHERAPY
- 1869P Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
- The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
- Role of enzyme replacement therapy for exocrine and nutritional insufficiency in patients with malignancies: A review
- Chemotherapy in combination with bevacizumab in breast cancer. Results of the observational study in daily clinical practice